Introduction: the challenge of multiresistance

David Livermore*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

52 Citations (Scopus)

Abstract

Antibiotic resistance is selected by antibiotic usage, which, in hospitals at least, is likely to increase driven by changes in demography, international development and advances elsewhere in medicine. Maintaining mankind's ability to treat infection therefore depends on better utilisation of present antimicrobials - better regimens as well as less unnecessary use - and on better infection control, but also on the development of new vaccines and antibiotics. Current developments include a raft of new agents active against meticillin-resistant Staphylococcus aureus (MRSA), but few that offer any advance against Gram-negative organisms. One that does have increased anti-Gram-negative activity, compared with earlier analogues, is tigecycline, a glycylcycline derivative of minocycline.

Original languageEnglish
Pages (from-to)S1-S7
JournalInternational Journal of Antimicrobial Agents
Volume29
Issue numberSUPPL. 3
DOIs
Publication statusPublished - May 2007

Bibliographical note

Funding Information:
The supplement has been funded by an unrestricted educational grant from Wyeth UK. Wyeth UK have had no input into the content or editorial.

Keywords

  • Antibiotic development
  • Multiresistance
  • Resistance control

Fingerprint

Dive into the research topics of 'Introduction: the challenge of multiresistance'. Together they form a unique fingerprint.

Cite this